Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Juno Therapeutics
307 Westlake Avenue North, Suite 300
Seattle, WA 98109
Phone: 206-696-0703

Juno is a clinical stage company that brings together three of the world's leading cancer centers - Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute - in unique partnership to advance a broad pipeline of potential curative immunotherapy treatments. With one of the largest ever Series A investments for a biotech startup, Juno will build on breakthroughs in the design of novel immunotherapies to develop two distinct and complementary platforms - chimeric antigen receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. Juno's goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.

Key Contact
Name
Hans Bishop
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
01/14/14 $145,000,000 Series A Venrock
undisclosed
08/05/14 $134,000,000 Series B Alaska Permanent Fund
ARCH Venture Partners
Crestline Investors
Venrock
undisclosed